Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 4, 2009, Pages 300-305

  Yu, Ying Nan ^a   Chen, Hui ^a   Li, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; AMINOTRANSFERASE; BICYCLOL; CATALASE; CISPLATIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; LIVER PROTECTIVE AGENT; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INDUCTION; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER PROTECTION; LIVER TOXICITY; MALE; MOUSE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; L-LACTATE DEHYDROGENASE; LIVER; LIVER DISEASES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE SYNTHASE TYPE II; TRANSAMINASES; TYROSINE;

ANIMALIA; MUS;

EID: 62549149380     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00343.x     Document Type: Article

References (41)

1. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998 34 : 1522 34.
2. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007 33 : 177 90.
3. Van Basten JP, Schrafford-Koops H, Sleijfer DT, Pras E, Van Driel MF, Hoekstra HJ. Current concept about testicular cancer. Eur J Surg Oncol 1997 23 : 354 60.
4. Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer-current controversies and future directions. Cancer Treat Rev 2004 430 : 343 58.
5. Thigpen T, Vance R, Puneky L, Khansurt T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994 55 : S97 107.
6. Pectasides D, Pectasides M, Maria Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer. Eur Urol 2005 48 : 60 7.
7. Pectasides D, Pectasides M, Psyrri A, Koumarianou A, Xiros N, Pectasides E et al. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. Cancer Invest 2006 24 : 780 5.
8. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002 99 : 4592 5.
9. Vermorken JB, Pinedo, HM. Gastrointestinal toxicity of cis-diamminedichloroplatinum (II). Neth J Med 1982 25 : 270 4.
10. Cavalli F, Tschopp L, Sonntag RW, Zimmerman A. A case of liver toxicity following cis-dichlorodiammineplatinum (II) treatment. Cancer Treat Rep 1978 62 : 2125 6
11. Pollera CF, Meglio F, Nardi M, Vitelli G, Morolla P. Cisplatin-induced hepatic toxicity. J Clin Oncol 1987 5 : 318 9
12. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharm 1993 27 : 438 41
13. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 1997 23 : 20 40.
14. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000 57 : 1229 35.
15. Siddik, ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003 22 : 7265 79.
16. Sadzuka Y, Shoji T, Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992 43 : 1873 5.
17. Yilmaz HR, Sogut S, Ozyurt B, Ozugurlu F, Sahin S, Isik B et al. The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health 2005 21 : 67 73.
18. Srivastava RC, Farookh A, Ahmad N, Misra M, Hasan SK, Husain MM. Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats. Biometals 1996 9 : 139 42.
19. Obata T. Nitric oxide and depolarization induce hydroxyl radical generation. Jpn J Pharmacol 2002 88 : 1 5.
20. Eiserich JP, Patel RP, O'Donnell VB. Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules. Mol Aspects Med 1998 19 : 221 357.
21. Radi, R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004 101 : 4003 8.
22. Chirino YI, Hernandez-Pando R, Pedraza-Chaveri, J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 2004 4 : 20 9.
23. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004 195 : 221 30.
24. Zicca A, Cafaggi S, Mariggio MA, Vannozzi MO, Ottone M, Bocchini V et al. Reduction of cisplatin hepatotoxicity by procainamidehydrochloride in rats. Eur J Pharmacol 2002 442 : 265 72.
25. Liu GT. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action. Chin J New Drug 2001 10 : 325 7.
26. Liu GT, Li Y, Wei HL, Zhang H, Xu JY, Yu LH. Mechanism of protective action of bicyclol against CCl4-induced liver injury in mice. Liver Int 2005 25 : 872 9.
27. Li Y, Li Y, Liu GT. Protective effects of bicyclol on liver fibrosis induced by carbon tetrachloride. Chin Med J 2004 84 : 2096 101.
28. Wang HP, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol 2006 534 : 194 201.
29. Li M, Liu GT. Inhibition of Fas/FasL mRNA expression and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. World J Gastroenterol 2004 10 : 1775 9.
30. Yao GB, Xu DZh, Lan P, Xu ChB, Wang Ch, Luo J et al. Efficacy and safety of bicyclol in treatment of 2200 chronic viral hepatitis. Chin J New Drugs Clin Rem 2005 24 : 421 6.
31. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990 36 : 1440 3.
32. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988 34 : 497 500.
33. Johansson LH, Borg LAH. A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem 1988 174 : 331 6.
34. Lowry O, Rosenbraugh N, Farr L, Rondall R. Protein measurement with the folin-phenol reagent. J Biol Chem 1951 193 : 265 75.
35. Zhao J, Chen H, Li Y. Protective effect of bicyclol on acute alcohol-induced liver injury in mice. Eur J Pharmacol 2008 586 : 322 31.
36. Lu H, Li Y. Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats. Acta Pharmacol Sin 2002 23 : 942 5.
37. Mansour MA, Mostafa AM, Nagi MN, Khattab MM, Al-Shabanah OA. Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats. Comp Biochem Physiol C Toxicol Pharmacol 2002 132 : 123 8.
38. Saleh S, El-Demerdash E. Protective effects of l-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005 97 : 91 7.
39. Li M, Liu GT. Inhibitory effect of bicyclol on iNOS expression and NF-κB activation degradation in marcrophages induced by lipopolysaccharides. Chin Pharmacol Bull 2006 22 : 1438 43
40. Hannemann J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 1988 51 : 119 32.
41. Aamdal S, Fodstad O, Pihl A. Some procedures to reduce cisplatinum toxicity reduce antitumour activity. Cancer Treat Rev 1987 14 : 389 95.